After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.... [Read More]
Cyltezo (adalimumab-adbm) may be interchanged for Humira (adalimumab) for all indications, according to an October decison by the FDA. The FDA has also approved a new combination of celecoxib and tramadol for pain management. ... [Read More]
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib… [Read More]
In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.... [Read More]
LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown… [Read More]
Hadlima (adalimumab-bwwd), which is biosimilar to adalimumab, is now FDA approved to treat multiple autoimmune diseases…... [Read More]
A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.... [Read More]
In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…... [Read More]
The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…... [Read More]
Health Canada has approved adalimumab for treating chronic non-infectious anterior uveitis in patients 2 years and older…... [Read More]